Adair K. Minihan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adair K. Minihan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Priti Bandi
Surveillance & Health Equity Science, American Cancer Society , Atlanta, GA
24 shared publications - Jessica Star
Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia
23 shared publications - Ahmedin Jemal
Surveillance, Prevention, and Health Services Research American Cancer Society Atlanta Georgia USA
22 shared publications - Robert A. Smith
Center for Early Cancer Detection American Cancer Society Atlanta Georgia USA
20 shared publications - Farhad Islami
American Cancer Society Surveillance and Health Equity Science Atlanta Georgia USA
19 shared publications - K. Robin Yabroff
Surveillance, Prevention & Health Services Research, American Cancer Society , Atlanta, GA
19 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
We present national and state representative prevalence estimates of modifiable cancer risk factors, preventive behaviors and services, and screening, with a focus on changes during the COVID-19 pandemic. Between 2019 and 2021, current smoking, physical inactivity, and heavy alcohol consumption declined, and human papillomavirus vaccination and stool testing for colorectal cancer screening uptake increased. In contrast, obesity prevalence increased, while fruit consumption and cervical cancer screening declined during the same timeframe. Favorable and unfavorable trends were evident during the second year of the COVID-19 pandemic that must be monitored as more years of consistent data are collected. Yet disparities by racial/ethnic and socioeconomic status persisted, highlighting the continued need for interventions to address suboptimal levels among these population subgroups.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
We present national and state representative prevalence estimates of modifiable cancer risk factors, preventive behaviors and services, and screening, with a focus on changes during the COVID-19 pandemic. Between 2019 and 2021, current smoking, physical inactivity, and heavy alcohol consumption declined, and human papillomavirus vaccination and stool testing for colorectal cancer screening uptake increased. In contrast, obesity prevalence increased, while fruit consumption and cervical cancer screening declined during the same timeframe. Favorable and unfavorable trends were evident during the second year of the COVID-19 pandemic that must be monitored as more years of consistent data are collected. Yet disparities by racial/ethnic and socioeconomic status persisted, highlighting the continued need for interventions to address suboptimal levels among these population subgroups.
- 24 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 289-298
Public health impact of increasing human papillomavirus vaccination and cervical cancer screening
Background: Cervical cancer poses a substantial burden in the United States. State-level decision makers need to understand the expected benefits of implementing interventions to reduce this burden. This study aimed to estimate the long-term state-level benefits of interventions to reduce the burden of cervical cancer. Methods: We used a simulation model to estimate the expected reductions in cervical cancer incidence and mortality by achieving 80% (or 90%) vaccination coverage among adolescents aged 13-17 years by 2030 and increasing screening uptake by 5% among women aged 21-65 years across all 50 US states who had never been screened. We modeled 1 status quo scenario and 3 intervention scenarios: increasing vaccination only, increasing screening only, and increasing both vaccination and screening. The benefits of each intervention were presented as the cumulative reduction in cancer incidence and mortality compared with the status quo over a 100-year analytic period. Results: Compared with the status quo, the cumulative reduction from the “increase in vaccination coverage only” scenario varied substantially by state, generally being higher in Southern and Western states. The greatest reductions were predicted for Mississippi, with 253.1 cases and 80.0 deaths per 100 000 women. The “increase in both vaccination and screening” scenario reduced cancer incidence from 9.2 (Utah) to 266.0 (Mississippi) per 100 000 women and reduced mortality from 3.3 (Utah) to 85.0 (Mississippi) per 100 000 women. Conclusion: Our modeling study suggests that states and regions will differ in the extent to which they will benefit from increasing human papillomavirus vaccination coverage and cervical cancer screening uptake.
- 24 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 289-298
Public health impact of increasing human papillomavirus vaccination and cervical cancer screening
Background: Cervical cancer poses a substantial burden in the United States. State-level decision makers need to understand the expected benefits of implementing interventions to reduce this burden. This study aimed to estimate the long-term state-level benefits of interventions to reduce the burden of cervical cancer. Methods: We used a simulation model to estimate the expected reductions in cervical cancer incidence and mortality by achieving 80% (or 90%) vaccination coverage among adolescents aged 13-17 years by 2030 and increasing screening uptake by 5% among women aged 21-65 years across all 50 US states who had never been screened. We modeled 1 status quo scenario and 3 intervention scenarios: increasing vaccination only, increasing screening only, and increasing both vaccination and screening. The benefits of each intervention were presented as the cumulative reduction in cancer incidence and mortality compared with the status quo over a 100-year analytic period. Results: Compared with the status quo, the cumulative reduction from the “increase in vaccination coverage only” scenario varied substantially by state, generally being higher in Southern and Western states. The greatest reductions were predicted for Mississippi, with 253.1 cases and 80.0 deaths per 100 000 women. The “increase in both vaccination and screening” scenario reduced cancer incidence from 9.2 (Utah) to 266.0 (Mississippi) per 100 000 women and reduced mortality from 3.3 (Utah) to 85.0 (Mississippi) per 100 000 women. Conclusion: Our modeling study suggests that states and regions will differ in the extent to which they will benefit from increasing human papillomavirus vaccination coverage and cervical cancer screening uptake.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
We present national and state representative prevalence estimates of modifiable cancer risk factors, preventive behaviors and services, and screening, with a focus on changes during the COVID-19 pandemic. Between 2019 and 2021, current smoking, physical inactivity, and heavy alcohol consumption declined, and human papillomavirus vaccination and stool testing for colorectal cancer screening uptake increased. In contrast, obesity prevalence increased, while fruit consumption and cervical cancer screening declined during the same timeframe. Favorable and unfavorable trends were evident during the 2nd year of the COVID-19 pandemic that must be monitored as more years of consistent data are collected. Yet disparities by racial/ethnic and socioeconomic status persisted, highlighting the continued need for interventions to address suboptimal levels among these population subgroups.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
We present national and state representative prevalence estimates of modifiable cancer risk factors, preventive behaviors and services, and screening, with a focus on changes during the COVID-19 pandemic. Between 2019 and 2021, current smoking, physical inactivity, and heavy alcohol consumption declined, and human papillomavirus vaccination and stool testing for colorectal cancer screening uptake increased. In contrast, obesity prevalence increased, while fruit consumption and cervical cancer screening declined during the same timeframe. Favorable and unfavorable trends were evident during the 2nd year of the COVID-19 pandemic that must be monitored as more years of consistent data are collected. Yet disparities by racial/ethnic and socioeconomic status persisted, highlighting the continued need for interventions to address suboptimal levels among these population subgroups.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Obesity and smoking prevalence by state from 2019 to 2021.
- 4 January 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (4) , 613-617
Colorectal cancer screening test exposure patterns in US adults 45 to 49 years of age, 2019-2021
Several organizations now recommend that individuals at average risk for colorectal cancer (CRC) begin screening at 45 rather than 50 years of age. We present contemporary estimates of CRC screening in newly eligible adults aged 45 to 49 years between 2019 and 2021. Nationally representative prevalence estimates and population number screened were estimated based on the National Health Interview Survey. A logistic regression model assessed CRC screening prevalence differences by survey year and sociodemographic characteristics. In 2021, 19.7%—that is, fewer than 4 million of the eligible 19 million adults aged 45 to 49 years—were up-to-date on CRC screening. Screening was lowest in those who were uninsured (7.6%), had less than a high school diploma (15.4%), and Asian (13.1%). Additionally, fecal occult blood test and/or fecal immunochemical testing was underused, with only 2.4% (<460 000 people) reporting being up-to-date with screening using this modality in 2021. CRC screening in eligible young adults remains low. Concerted efforts to improve screening are warranted, particularly in underserved populations.
- 4 January 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (4) , 613-617
Colorectal cancer screening test exposure patterns in US adults 45 to 49 years of age, 2019-2021
Several organizations now recommend that individuals at average risk for colorectal cancer (CRC) begin screening at 45 rather than 50 years of age. We present contemporary estimates of CRC screening in newly eligible adults aged 45 to 49 years between 2019 and 2021. Nationally representative prevalence estimates and population number screened were estimated based on the National Health Interview Survey. A logistic regression model assessed CRC screening prevalence differences by survey year and sociodemographic characteristics. In 2021, 19.7%—that is, fewer than 4 million of the eligible 19 million adults aged 45 to 49 years—were up-to-date on CRC screening. Screening was lowest in those who were uninsured (7.6%), had less than a high school diploma (15.4%), and Asian (13.1%). Additionally, fecal occult blood test and/or fecal immunochemical testing was underused, with only 2.4% (<460 000 people) reporting being up-to-date with screening using this modality in 2021. CRC screening in eligible young adults remains low. Concerted efforts to improve screening are warranted, particularly in underserved populations.